Heterogeneity in the pathology and molecular biology of breast cancer

Current Genomics

Volumn 3, Issue 5, 2002, Pages 477-488

  Gabrielson, Edward ^a   Argani, Pedram ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CARCINOGENESIS; CANCER STAGING; CELL HETEROGENEITY; CLINICAL FEATURE; COMPLEX FORMATION; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOLECULAR MODEL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0036782225     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389202023350327     Document Type: Review

References (82)

1. Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization
2. Observer variability in reporting of breast lesions
3. Borderline epithelial lesions of the breast
4. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria
5. Ductal carcinoma in situ: Introduction of the concept of ductal intraepithelial neoplasia
6. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia
7. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy
8. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment
9. Clinical and pathologic correlation with mammographic findings in lobular carcinoma in situ
10. Lobular carcinoma in situ: Current concepts and controversies
11. Bilaterality of cancer of the breast. Biopsy of the opposite breast
12. Lobular carcinoma of the breast
13. Lobular carcinoma in situ of the breast. Long-term followup
14. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast. cancer
15. Genetic divergence in the clonal evolution of breast cancer
16. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
17. Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast
18. Molecular genetic studies of early breast cancer evolution
19. Loss of heterozygosity in ductal carcinoma in situ of the breast
20. Atypical ductal hyperplasia of the breast: Clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p
21. Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci on 8p, l3q, l6q, 17p and l7q
22. Allelic loss and the progression of breast cancer
23. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast
24. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast
25. The classification of ductal carcinoma in situ and its association with biological markers
26. Immunophenotype of intraductal carcinoma
27. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
28. Risk factors for breast cancer in women with proliferative breast disease
29. Atypical hyperplastic lesions of the female breast. A long-term follow- up study
30. Loss of heterozygosity in fibrocystic change of the breast: Genetic relationship between benign proliferative lesions and associated carcinomas
31. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications
32. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas
33. E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis
34. Invasive lobular carcinoma of the breast: Incidence and variants
35. Tubulolobular invasive breast cancer: A variant of lobular invasive cancer
36. Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation
37. Contralateral breast cancer: Annual incidence and risk parameters
38. Signet ring carcinoma of the female breast: A clinicopathologic analysis of 24 cases
39. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma
40. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast
41. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain
42. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas
43. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas
44. Separating favorable from unfavorable prognostic markers in breast cancer: The role of E-cadherin
45. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast
46. Tubular carcinoma of the breast. Clinical and pathological observations concerning 135 cases
47. Prognostic factors in primary mucinous breast carcinoma
48. Genomic alterations in tubular breast carcinomas
49. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
50. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers
51. Tumor suppressor p53 mutations and breast cancer: A critical analysis
52. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas
53. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer
54. Loss of heterozygosity events impeding breast cancer metastasis contain the MTAl gene
55. Progression model for pancreatic cancer
56. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases
57. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue
58. Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer
59. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells
60. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas
61. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
62. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
63. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
64. Molecular portraits of human breast tumours
65. Predicting the clinical status of human breast cancer by using gene expression profiles
66. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
67. Genetic heterogeneity in ductal carcinoma of the breast
68. Chromosome analysis of 97 primary breast carcinomas: Identification of eight karyotypic subgroups
69. A mutator phenotype in cancer
70. Genetic instabilities in human cancers
71. Human DNA repair genes
72. Organ site specificity for cancer in chromosomal instability disorders
73. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
74. Cancer of the microsatellite mutator phenotype
75. Microsatellite instability is uncommon in breast cancer
76. Genetic instability in colorectal cancers
77. Mutations of mitotic checkpoint genes in human cancers
78. Chromosomal stability and the DNA double-stranded break connection
79. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway
80. In search of the tumour-suppressor functions of BRCA1 and BRCA2
81. Alterations in DNA methylation: A fundamental aspect of neoplasia
82. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression